Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days.

Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with 50% diluted baby shampoo for three days.

Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with Blephaclean Sterile Eyelid Wipes (Thea Pharmaceuticals) for three days.

Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with tea tree oil shampoo for three days.

Demodex Infestation

Demodicosis

Cataract

Twice a day eyelid margin cleansing for three days.

Tea Tree Oil Shampoo

Applied topically in the eyelid margin every four hours for three days.

Ciprofloxacin Ophthalmic Ointment 0.3%

Baby shampoo

Blephaclean

Hospital de la Luz

Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery

A Randomized Controlled Trial of Treatment Efficacy in Ameliorating Demodex Spp. Infestation Among Cases Undergoing Cataract Surgery

Number of demodex (egg, larvae, nymph, adult-form) spp. per eyelash (taken from epilation).

Number of demodex (egg, larvae, nymph, adult-form) spp. in total (taken from epilation).

Number of cases diagnosed with endophthalmitis in the postoperative period.

Andric C Perez-Ortiz, M.D., M.P.H.

Clinical Professor

Hospital de La Luz

Claudia Palacio Pastrana, M.D., M.Sc.

Samuel J. Avalos Lara, M.D.

Hector Perez Cano, Ph.D.

Bani Antonio-Aguirre, M.D., M.P.H.c.

Cristina Mendoza-Velasquez, M.D., M.Sc.

Azyadeh Camacho-Ordóñez, M.D., M.Sc.c.

Andric C. Perez-Ortiz, M.D., M.P.H.

Patients diagnosed with Demodex spp. infestation undergoing cataract surgery were randomly allocated into four comparison groups a control group (standard treatment) and three new modalities of Demodex therapy (Blephaclean, baby shampoo, and tea tree oil) + conventional treatment.

Investigators and outcomes assessors were blinded to the treatment allocation of each participant. Outcome assessors were anterior segment surgeons who evaluated cases prior to cataract surgery. There was no indication of group allocation in the electronic medical records (EMR), only the participation of each candidate in the study. Similarly, investigators were blinded to group allocation and only recorded data directly from EMR. Blinding was kept after data analysis.

optimel manuka eyedrops 10 ml used as directed in a CAC (Conjunctival allergen challenge) study

sterile normal saline eyedrops used as directed in a CAC (conjunctival allergen challenge) study

Allergic Conjunctivitis

manuka eyedrops applied to the ocular surface

Manuka honey

Toyos Clinic

Manuka Eye Droops for Treatment of Allergy

A Phase 4 Study to Assess the Clinical Efficacy and Safety of Manuka Eye Drops for Treatment of Allergy

on a scale from 0-100 where 0 =no itching and 100=maximal itching subtracted scores measured for placebo treatments at visits 3B, 4 and 5

on a scale from 0-100 where 0=no hyperemia and 100=maximal hyperemia subtracted scores from placebo treatments at visits 3B, 4 and 5

If requested, data records without identifying patient information could be shared

randomized, double-blind placebo controlled

medications will be covered by blank labels

Cliradex® is a novel over-the-counter eyelid wipe which contains the most active ingredient of TTO. Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis.

Lid 'n Lash® Hygiene, is an over-the-counter eyelid wipe, without any medicinal ingredients,

Blepharitis

Meibomian Gland Dysfunction

Participants will use the Cliradex® eyelid hygiene lid wipe / towelette for BID for 2 weeks

Tea Tree Oil (TTO)

Patients will use the I-Lid'n Lash® Hygiene lid wipe / towelette for BID for 2 weeks

I-Lid'n Lash® Hygiene

Ottawa Health Research Institute

Antimicrobial and Clinical Efficacy of Cliradex® as Compared With I-Lid'n Lash® Hygiene in Treating Blepharitis

Antimicrobial and Clinical Efficacy of Cliradex® as Compared With I-Lid'n Lash® Hygiene in Treating Blepharitis: A Randomized, Outcomes-Assessor Masked, Clinical Trial

difference in change in the number of CFU's after 2 weeks treatment, between the groups. (Note: colony counts over 200 will not be counted but reported as >200)

The Secondary Outcome Measure will be the difference in change in objective clinical signs and symptoms using a visual grading scale

The Secondary Outcome Measure will be the difference in change in objective clinical signs and symptoms using a questionnaire after 2 weeks treatment between the groups.

difference in change in the number of CFU's at 2 & 4 weeks post discontinuation of treatment, between the groups. (Note: colony counts over 200 will not be counted but reported as >200)

The Outcome Measure will be the difference in change in objective clinical signs and symptoms using a visual grading scale

The Outcome Measure will be the difference in change in objective clinical signs and symptoms using a questionnaire

Ottawa Hospital Research Institute

This study is a single-centre, randomized, outcomes-assessor masked trial with two groups. Patients with chronic blepharitis will be randomized into either the Cliradex® eyelid hygiene or I-Lid 'n Lash® Hygiene group.
There will be 20 participants enrolled in each group. Although both eyes will receive treatment, only the worse eye will be enrolled in the study. In addition to randomizing the participants into treatment group they will also be placed by chance into either the 3 visit or 4 visit group (n=10 per group).

Information concerning the group the patient was randomized into will not be available to the physicians that will see the participants at future appointments and grade their outcomes (masked assessor).
All microbiology readers will be masked to treatment group allocation.

8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.

9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.

8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Terpinen-4-ol: Lid scrub once or twice per day for one month.

Terpinen-4-ol Treatment Arm

9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Placebo: Lid scrub once or twice per day for one month

Placepo Pads Contol Arm

Total

Sex: Female, Male

Region of Enrollment

Change in mites count after treatment compared to the baseline data. If the mites' count remains zero during the last two visits, it is considered "complete eradication". Patients without achieving complete eradication will be categorized as "incomplete eradication".

10 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (5 patients each) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Terpinen-4-ol: Lid scrub once or twice per day for one month.

10 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 each) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
Placebo: Lid scrub once or twice per day for one month

Change in the Number of Demodex Mites

Lid margin redness and bulbar conjunctival hyperemia were each assessed using an ordered categorical value ranging from 0 (None) to 3 (Severe). The two scores were summed to obtain the final score, which ranges from 0 (None) to 6 (Severe).

Change in Lid Margin Redness and Bulbar Conjunctival Hyperemia

Overall Study

Hosam El Sheha, MD, PhD

Chronic Blepharitis

Lid scrub once or twice per day for one month.

Terpinen-4-ol

Lid scrub once or twice per day for one month

Placebo

Ocular Surface Center

Demodex Blepharitis Treatment Study

Safety and Efficacy of Single-use Terpinen-4-ol Pads for Treating Ocular Mites A Randomized Clinical Trial

Tissue Tech Inc.

National Eye Institute (NEI)

Tea Tree Oil shampoo 0.25% and ointment 5% daily and Tea Tree Oil oily solution 50% once a week for six weeks

blepharitis/leptospermum scoparium

Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery

Manuka Eye Droops for Treatment of Allergy

Antimicrobial and Clinical Efficacy of Cliradex® as Compared With I-Lid'n Lash® Hygiene in Treating Blepharitis

Demodex Blepharitis Treatment Study

Tea Tree Oil in the Treatment of Chronic Blepharitis

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen